

Long-Term Outcomes of Sutureless Intrasccleral Fixation of Intraocular Lens with Pars Plana Vitrectomy in Patients with Posterior or Panuveitis

Lisa J. Faia MD

Associated Retinal Consultants, P.C.

Oakland University William Beaumont School of Medicine

53rd Annual Scientific Meeting - The Retina Society 2020 VR

August 25, 2020



Financial Disclosure

- ◆ Consultant: Allergan, Santen, Genetech, Bausch & Lomb, EyePoint Pharmaceuticals
- ◆ Speaker: Allergan, AbbVie, Genetech

Summary

- ◆ This study describes the long-term outcomes of sutureless intrascleral intraocular lens fixation with pars plana vitrectomy in eyes with a history of posterior or panuveitis.
- ◆ Long-term visual improvement, infrequent complications, and a low rate of uveitis reactivation were seen.
- ◆ Given the extensive variability of uveitis patients, we suggest that eyes with a history of significant inflammation be monitored closely after surgery.

Introduction

- ◆ Sutureless intrascleral fixation of intraocular lens (SIS IOL) with pars plana vitrectomy (PPV) has been shown to have favorable anatomical and visual outcomes.
- ◆ Patients with uveitis have a higher rate of IOL dislocation following routine cataract surgery.
- ◆ For patients with a history of uveitis, the literature is limited for long-term outcomes of SIS IOL with PPV.

Purpose


- ◆ To report the long-term outcomes of sutureless intrascleral fixation of secondary intraocular lens (SIS IOL) with pars plana vitrectomy (PPV) in eyes with posterior or panuveitis.

Method

- ◆ Retrospective, consecutive case series from multiple surgeons of a single center performing scleral fixation of intraocular lenses (IOLs) in uveitis patients from October 1, 2013 to September 31, 2018.
- ◆ **Primary outcomes measures** included post-operative IOL status and reactivation of uveitis at last follow up.
- ◆ **Secondary outcome measures** included difference in outcomes with peri-operative steroid and/or pre-operative immunosuppressive therapy.

Methods

- ◆ *Inclusion criteria* included eyes that underwent SIS IOL with PPV, were previously diagnosed with posterior or panuveitis, and had at least 3 months of inactivity of uveitis prior to surgery.
- ◆ *Exclusion criteria* were eyes diagnosed with anterior uveitis or those that had follow up of less than 1 year.
- ◆ Clinic notes, imaging, and operative reports were reviewed, and age, sex, laterality, visual acuity (VA), refraction, medication use, examination and imaging findings, complications, and surgical technique were collected.



Results

Table 1: Baseline Characteristics of 13 Eyes with Posterior or Panuveitis that Underwent Successful Intracapsular Fixation of Intraocular Lens with Pars Plana Vitrectomy

Age, mean \pm SD	51.7 \pm 21.0 years
Gender (%)	
Female	10 (81)
Male	3 (17)
Type of Uveitis (%)	
Panuveitis	7 (58)
Posterior Uveitis	3 (42)
Etiology of Uveitis (%)	
Idiopathic	6 (58)
Rheumatoid arthritis	4 (33)
Sarcoidosis	3 (17)
Surgical Indication (%)	
Dislocated intraocular lens	6 (58)
Aphakia	3 (23)
Retained lens fragments	2 (17)
Dislocated crystalline lens	1 (8)
Pre-operative logMAR, mean \pm SD	1.23 \pm 0.72
Pre-operative Immunosuppressive Therapy Use (%)	6 (50)
Post-operative Oral Steroid Use (%)	6 (58)
Mean Follow Up Time, years (range)	3.1 (1.0 to 6.3)

SD = standard deviation

Results

- ◆ Mean follow up time was 3.1 years (range 1.0 - 6.3 years).
- ◆ Post-operative IOL dislocation occurred in 2 eyes (of 12, 17%) at follow up times of 5.5 and 6.0 months.
- ◆ Reactivation of uveitis occurred in 4 eyes (33%) at mean follow up of 19.4 ± 6.3 months in 2 eyes with pre-operative immunosuppression and 2 eyes with peri-operative steroids.

Results

Table 1: Post-operative Findings at Last Follow Up of 12 Eyes with Posterior or Pannusitis that Underwent Sutureless Intracapsular Fixation of Intraocular Lens with Pars Plana Vitrectomy

	LogMAR VA	Spherical Equivalent (D)	Eyes with IOL Dislocation (%)	Eyes with Reactivation of Uveitis (%)
All Patients (n=12)	0.78±0.34	-0.92±1.54	2 (17)	4 (33)
Pre-operative Steroids Use				
Yes (n=6)	0.53±0.36	-0.40±1.82	2 (33)	2 (33)
No (n=6)	0.99±0.34	-1.44±1.86	0 (0)	2 (33)
	p=0.81	p=0.35		
Pre-operative IMT Use				
Yes (n=6)	0.58±0.36	-0.85±1.26	2 (33)	2 (33)
No (n=6)	0.57±0.38	-0.98±1.53	0 (0)	2 (33)
	p=0.94	p=0.91		

VA = visual acuity

IOL = intraocular lens

n = number of eyes

D = diopters

IMT = immunomodulatory therapy

Limitations and Strengths

◆ Limitations

- ◆ Retrospective nature
- ◆ No standardization of peri-operative steroid use and treatment protocols for reactivation of uveitis
- ◆ Differences in surgical technique among the surgeons, such as the gauge of cannulas used for vitrectomy and IOL haptic externalization

◆ Strengths

- ◆ Sample size in comparison to prior studies
- ◆ Length of follow up
- ◆ Inclusion of only eyes with posterior or panuveitis

Conclusion

- ◆ Long-term outcomes of SIS IOL with PPV in eyes with posterior or panuveitis revealed infrequent complications.
- ◆ Statistically significant visual improvement was seen in this cohort.
- ◆ There was a low rate of uveitis reactivation and its occurrence was well beyond what one would expect from the timing of the surgical procedure.